Biologics & Specialty Drugs Billing

We’ll provide an overview of biologics and specialty drugs billing, including:

• Definition and examples of biologics and specialty drugs
• Why they are different from traditional drugs
• Special billing procedures and requirements
• Common billing codes
• Coverage and reimbursement challenges
• Strategies for managing specialty drug costs

Some common examples of biologics include:

• Monoclonal antibodies: Used to treat cancer, autoimmune disorders, and more
• Cytokines: Treat cancer and immune disorders
• Enzymes: Used for enzyme replacement therapy
• Vaccines: Prevent infectious diseases
• Blood components: Used for transfusions and therapies

Biologics and specialty drugs have unique features that differentiate them from traditional prescription medications:

• Intricate molecular structure, requires advanced manufacturing and handling
• Treat serious, often chronic illnesses
• Small patient populations, for rare diseases
• Require injection/infusion, can’t take by mouth
• Expensive, high development and production costs
• Extra patient monitoring required
• Short shelf life, special storage and handling
• Higher risk of side effects

These differences mean biologics and specialty drugs require special procedures for billing, reimbursement, and cost management.

Billing for biologics and specialty drugs has some unique coding, coverage, and reimbursement requirements:

Coding

• Require specific J-codes, C codes, Q codes, and other specialty codes
• May need multiple codes for dose, drug, and administration
• Modifiers important for identifying wasted drugs, partial fills

Patient Financial Assistance

• Copays can be $100s or $1,000s per month
• Manufacturers often provide copay cards and patient assistance programs

Prior Authorization

• Almost always requires prior authorization from insurance
• Detailed medical necessity documentation needed
• Eligibility criteria may apply (failed other therapies, lab values, etc)

Site of Care

• Where drug is administered affects billing (home vs clinic vs hospital)
• Hospital outpatient billing has higher reimbursement rates

Billing Challenges

• Payers may deny claims due to high costs
• Medical vs. pharmacy benefit coverage inconsistencies
• Require reauthorization for ongoing treatment

Accurate coding and detailed documentation is critical for getting reimbursed for these expensive drugs. Having a streamlined process for prior authorizations and financial assistance programs is also key.

There are certain billing codes that are commonly used for specialty drugs and biologics:

J-Codes: Used for Injectable/Intravenous Drugs Administered by a Healthcare Professional

Examples:

• J1745 Injection, infliximab, 10 mg (Remicade for rheumatoid arthritis)
• J9355 Injection, trastuzumab, 10 mg (Herceptin for breast cancer)
• J9041 Injection, bortezomib, 0.1 mg (Velcade for multiple myeloma)
• J9000 Injection, doxorubicin hydrochloride, 10 mg (Adriamycin chemotherapy)
• J0139 Injection, adalimumab, 1 mg (Humira for autoimmune disorders)

C-Codes: Temporary Pass-Through Codes for Certain Injectable or Infused Drugs

Examples:

• C9399 Unclassified drugs or biologicals (used if no permanent code exists yet)
• C9257 Injection, bevacizumab, 0.25 mg (Avastin, intravitreal use)

Q-Codes: Include Temporary Codes for Certain Specialty Drugs and Cell/Gene Therapies

For example:

• Q2040 Tisagenlecleucel, up to 250 million CAR-positive viable T cells, including leukapheresis and dose preparation, per infusion (Kymriah, a CAR-T cell therapy)

One category commonly used for specialty drugs is:

S-Codes: Used by Some Private Payers for Drugs and Services Without a National Code

For example:

• S0142 Colistimethate sodium, inhalation solution, administered through DME, concentrated form, per mg (an inhaled antibiotic for drug-resistant respiratory infections, often used in cystic fibrosis)

Due to their high costs, specialty drugs often face coverage and reimbursement difficulties:

• Non-covered drugs: Payers may exclude certain expensive specialty drugs from coverage
• High co-insurance: Patients pay 20-50% or more in coinsurance versus flat copay
• Medical vs pharmacy benefit inconsistencies: Each has different rules for utilization management, patient cost sharing
• Step therapy requirements: Must try cheaper therapies first and fail
• High prior authorization denial rates: For cost control and utilization management
• Lower reimbursement for clinics/hospitals: Makes it financially challenging to stock and administer specialty drugs
• State Medicaid restrictions: Varying coverage, utilization limits, and reimbursement rates

Due to extremely high prices, strategies for controlling specialty drug spending are important for providers and payers:

• Strict utilization management: Prior authorization, quantity limits, step therapy
• Contracting with limited pharmacies: For affordable access and distribution
• Copay maximization programs: Setting copays at insurance maximums allowed
• 340B drug discount program: Requires drug manufacturers to provide outpatient drugs to eligible health care organizations at significantly reduced prices
• Evidence-based prescribing: Following guidelines for appropriate use
• Biosimilars: Using lower cost alternative versions when possible
• Outcomes-based contracts: Contracts link payment for medications to improved patient outcomes
• Coupon adjustments: Removing value of manufacturer copay coupons from insurer payment
• Site of care management: Using lower cost sites, like infusion centers instead of hospitals